PLURONIC FT L 61

PLURONIC FT L 61

PLURONIC FT L 61

CAS No. : 9003-11-6

EC No. : 618-355-0

Synonyms:

Poloxalene; Poloxamer 188; POLOXAMER; Pluronic; Poloxalkol; 9003-11-6; Pluronic L 61; Pluronic L-81; Detalan; Pluracare; Therabloat; Tergitol XH; Lutrol F; Adeka Pluronic F 108; Epan 485; Epan 710; Epan 785; Cirrasol ALN-WS; 106392-12-5; Pluronic L44; Polyoxamer 108; Poloxamer 407; Poloxamer-188; Pluronic F 38; Pluronic F108; Pluronic F127; Tergitol nonionic XH; Antarox 17R4; Antarox 25R2; Antarox B 25; Antarox F 68; Antarox F 88; Antarox F 88FL; Antarox L 72; Antarox P 84; Daltocel F 460; Slovanik M-640; Antarox F 108; Antarox P 104; Antarox SC 138; Emulgen PP 230; Adeka 25R1; Adeka 25R2; Adeka L 61; Dehypon KE 3557; Empilan P 7068; Proxanol; Arcol E 351; D 500 (polyglycol); Polyethylene-polypropylene glycol; Arco Polyol R 2633; Epan 450; Crisvon Assistor SD 14; Pluronic L; Breox BL 19-10; Epan U 108; Proxanol Tsl-3; Pluronic F77; Pluronic F87; Pluronic F88; Pluronic L62; Pluronic L64; Pluronic P65; Pluronic P84; Pluronic P85; Meroxapol 105; Poloxamer 101; Crl 1005; Pluronic P103; Pluronic P104; Pluronic P105; BASF-L 101; Pluronic L 122; Polyethylene glycol, propoxylated; Ethylene oxide-propylene oxide block polymer; Glycols, polyethylene-polypropylene; BSP 5000; CRL 1605; CRL 8131; CRL 8142; Oxirane, methyl-, polymer with oxirane, block; RC 102; Oxirane, methyl-, polymer with oxirane; Methyloxirane polymer with oxirane block; SK&F 18,667; F 77; F 87; F 88; P 84; P 85; B 053; F 108; F 127; P 103; P 104; P 105; P 123; PEG/PPG-125/30 Copolymer; HSDB 7222; NSC 63908; Polyethylene oxide-polypropylene oxide; Vepoloxamer (USAN); Vepoloxamer [USAN]; Polyoxyethylene-oxy-propylene [French]; Poly(ethylene oxide-co-propylene oxide); Polyoxyethylene – polyoxypropylene copolymer; F-108; Ethylene oxide-propylene oxide block copolymer dipropylene glycol ether; Ethylene oxide-propylene oxide block copolymer ether with ethylene glycol; Polyoxyethylene – polyoxypropylene block copolymer; alpha-Hydro-omega-hydroxypoly(oxyethylene)(sub a)-poly(oxopropylene)(sub b)-poly(oxyethylene)(sub a) block copolymer; alpha-Hydro-omega-hydroxypoly(oxyethylene)a-poly(oxopropylene)b-poly(oxyethylene)a block copolymer; 75-H-1400; C10H22O3; 2-methyloxirane; oxirane; Poloxamer [USAN:INN:BAN]; Pluracol V; Pluriol PE; component of Casakol; Pluronic L122; Lutrol F (TN); oxirane-propylene oxide; Pluriol PE 6810; PEG-PPG-PEG; ETS9O8IMRZ; UNII-ETS9O8IMRZ; Eban 710; Epan 750; Epon 420; UNII-66UUC8WX0D; 66UUC8WX0D; Niax 16-46; UNII-199SZS8E2Q; UNII-JP0CK963E0; UNII-P5QZM4T259; SCHEMBL11737; ethylene oxide propylene oxide; Oxirane, polymer with oxirane; UNII-1AZW43116L; UNII-52901V8XAR; Propylene Oxide Ethylene Oxide; TsL 431; ADEKA PLURONIC F-108; 199SZS8E2Q; JP0CK963E0; P5QZM4T259; UNII-68T8I45V23; CHEBI:32026; MST-188; TVM 370; 1AZW43116L; 52901V8XAR; Peg/ppg-24/34 triblock copolymer; Poloxalene [USAN:USP:INN:BAN]; NSC63908; NSC-63908; WS 661; AKOS015912614; Oxirane, 2-methyl-, polymer with oxirane, ether with 1,2-propanediol (2:1); Oxirane, methyl-, polymer with oxirane, ether with 1,2-propanediol (2:1); 68T8I45V23; DB11451; SK&F-18667; LS-72949; SK & F 18,667; LS-101081; N 480; D01941; D10680; M 90/20; 75H90000; .alpha.-Hydro-.omega.-hydroxypoly(oxyethylene)poly(oxypropylene)poly(oxyethylene) block copolymer

EN

PLURONIC FT L 61 IUPAC Name 2-methyloxirane;oxirane

PLURONIC FT L 61 InChI InChI=1S/C3H6O.C2H4O/c1-3-2-4-3;1-2-3-1/h3H,2H2,1H3;1-2H2

PLURONIC FT L 61 InChI Key RVGRUAULSDPKGF-UHFFFAOYSA-N

PLURONIC FT L 61 Canonical SMILES CC1CO1.C1CO1

PLURONIC FT L 61 Molecular Formula C5H10O2

PLURONIC FT L 61 CAS 691397-13-4

PLURONIC FT L 61 European Community (EC) Number 618-355-0

PLURONIC FT L 61 NSC Number 63908

PLURONIC FT L 61 RTECS Number TP5950000

PLURONIC FT L 61 DSSTox Substance ID DTXSID70872897

PLURONIC FT L 61 Physical Description Liquid

PLURONIC FT L 61 Color/Form Liquid

PLURONIC FT L 61 Other Experimental Properties Vary from water-insoluble to very water-soluble compounds.

PLURONIC FT L 61 Molecular Weight 102.13 g/mol

PLURONIC FT L 61 Hydrogen Bond Donor Count 0

PLURONIC FT L 61 Hydrogen Bond Acceptor Count 2

PLURONIC FT L 61 Rotatable Bond Count 0

PLURONIC FT L 61 Exact Mass 102.06808 g/mol

PLURONIC FT L 61 Monoisotopic Mass 102.06808 g/mol

PLURONIC FT L 61 Topological Polar Surface Area 25.1 Ų

PLURONIC FT L 61 Heavy Atom Count 7

PLURONIC FT L 61 Formal Charge 0

PLURONIC FT L 61 Complexity 36.7

PLURONIC FT L 61 Isotope Atom Count 0

PLURONIC FT L 61 Defined Atom Stereocenter Count 0

PLURONIC FT L 61 Undefined Atom Stereocenter Count 1

PLURONIC FT L 61 Defined Bond Stereocenter Count 0

PLURONIC FT L 61 Undefined Bond Stereocenter Count 0

PLURONIC FT L 61 Covalently-Bonded Unit Count 2

PLURONIC FT L 61 Compound Is Canonicalized Yes

Mechanical cleansing of a wound with a sponge soaked in a surfactant has prevented the development of experimental wound infection. The surfactant utilized for wound cleansing is Pluronic F-68 (PLURONIC FT L 61; I), a member of a family of block copolymers called Pluronic polyls. Long term toxicity studies and clinical trials suggest that this surfactant is safe for human use. I is a nonionic detergent that does not have any intrinsic antibacterial activity. Although mechanical cleansing with saline-soaked sponges effectively removes bacteria, it damages the wound and impairs its resistance to infection. The severity of the damage to the skin exerted by the sponge can be correlated with its porosity. Sponges with a low porosity are abrasive and exert more damage to skin than do sponges with a higher porosity. The addition of I to even the most abrasive sponges ensures that the bacterial removal efficiency of the sponge scrub is maintained, while tissue trauma is minimized. This dual effect of the surfactant results in a dramatic reduction in the infection rate of contaminated wounds.A randomized, double blind, placebo controlled, dose escalation study of the toxicity and pharmacokinetics of poloxamer 188 (RheothRx) was conducted in 36 healthy male subjects (ages 19-35 yr) who received iv injections of 10-90 mg/kg/hr poloxamer or placebo. … The most common adverse effects were pain, injection site abnormality, and nausea. Eight subjects discontinued treatment with poloxamer due to adverse events.Absorption and excretion of 14C-PLURONIC FT L 61 2930 (PX), a nonionic hydrophobic surfactant of large molecular weight, were studied using bile fistula rats. Approximately half of the dose infused intraduodenally was absorbed and some of the absorbed surfactant was excreted in bile. The remainder was excreted in urine. Only trace quantities of the 14C-PX were recovered in liver and carcass at termination of the study. Two studies were also performed with 14C-PX incorporated into the diet. In the first feeding study of 7 days duration, most of the agent was excreted via the gastrointestinal tract within 72 hr of discontinuing treatment. In the second study, rats were fed dietary 14C-PX for 7, 14, or 23 days to determine whether the surfactant continued to accumulate in the body as the test period was extended. Further accumulation did occur between the 7th and 14th days but not when feeding was continued for a total of 23 days. Of the amount of 14C-PX ingested after 23 days of feeding, essentially all was excreted by the end of 7 days after discontinuing treatment. These studies indicate that despite its large molecular weight of about 3,000 some 14C-PX is absorbed. Furthermore, absorbed material is promptly excreted in bile and urine with little retained in body tissues.To investigate the distribution of poloxamer 407 (Pluronic F-127), rats received 300 mg of intraperitoneal poloxamer 407 solution; blood and urine samples were taken frequently and liver and kidney homogenates were prepared and analyzed using a colorimetry assay. Clearance was 0.014 mL/min. The mean amount excreted in the urine was 76.3 mg in 24 hr. Amounts of poloxamer 407 in supernatants of liver and kidney homogenates were 15.9 and 3.1 mg, respectively.The disposition and pharmacokinetics of Poloxamer 108 was studied in rats as an initial step towards understanding its behavior in man. After iv administration in rats, about 94% of 7 or 100 mg/kg doses of ethylene-14-C-labeled polymer was excreted in the urine in 3 days. About 6% of the label appeared in feces. Erythrocyte membranes were not permeable to the polymer, and only the parent compound was demonstrable in urine. Twenty hours after dosing, small residues were detectable only in the kidney, liver, small intestine and carcass. The 3rd phase of the plasma disappearance pattern was evident only at the larger dose, but plasma disappearance kinetics were independent of the dose in the used range. Most of Poloxamer 108 was eliminated rapidly in rats by renal excretion; a smaller portion probably was removed by biliary excretion.A randomized, double blind, placebo controlled, dose escalation study of the toxicity and pharmacokinetics of poloxamer 188 (RheothRx) was conducted in 36 healthy male subjects (ages 19-35 yr) who received iv injections of 10-90 mg/kg/hr poloxamer or placebo. Poloxamer was eliminated primarily by renal excretion. Estimates of clearance, elimination rate constant, and apparent volume of distribution at steady state were independent of infusion rate. Steady state plasma levels increased linearly with increasing infusion rate values up to 90 mg/kg/hr. Mean plasma clearance was 1.06 mL/min/kg.Analyte: PLURONIC FT L 61; matrix: chemical identification; procedure: visual reaction (blue color) with ammonium thiocyanate, cobalt nitrate and ethylene chloride.Analyte: PLURONIC FT L 61; matrix: chemical purity; procedure: ultraviolet absorption spectrophotometry with detection at 630 nm and comparison to standards.Oral dosage form new animal drugs: PLURONIC FT L 61. (a) Specifications. Polyoxypropylene-polyoxyethylene glycol nonionic block polymer. … Conditions of use. (1) For treatment of legume (alfalfa, clover) bloat in cattle. (2) For control of legume (alfalfa, clover) bloat in cattle. (3) For prevention of legume (alfalfa, clover) and wheat pasture bloat in cattle. (4) For control of legume (alfalfa, clover) and wheat pasture bloat in cattle.New animal drugs for use in animal feeds: PLURONIC FT L 61. (a) Approvals. (1) Dry Type A medicated articles: 53 percent to 000069 in 510.600(c) of this chapter. (2) Liquid Type A medicated articles: 99.5 percent to 000069 in 510.600(c) of this chapter. (b) Conditions of use. (1) For prevention of legume (alfalfa, clover) and wheat pasture bloat in cattle.New animal drugs for use in animal feeds: PLURONIC FT L 61 free-choice liquid Type C feed. (a) Approvals. Type A medicated articles: 99.5 percent to 066104 in 510.600(c) of this chapter. (b) Conditions of use. (1) For control of legume (alfalfa, clover) and wheat pasture bloat in cattle … (2) For control of legume (alfalfa, clover) bloat in cattle grazing of prebloom legumes.PLURONIC FT L 61 is a food additive permitted in feed and drinking water of animals.Acute Exposure/ Effect of hydrophobic surfactant, PLURONIC FT L 61 2930, on lipid absorption was studied in rats. Under acute conditions with surfactant infused intraduodenally with a lipid meal absorbed lipid accumulated abnormally in the enterocytes. This effect was quickly reversed after terminating treatment.PLURONIC FT L 61 2930, a hydrophobic surfactant, was incorporated into an atherogenic diet at dose levels, 0.5% and 1% of the diet, and fed to rabbits for 10 weeks. Another group received plain atherogenic diet alone and a control group was fed chow. After this period, serum lipoproteins were separated by centrifugation and analyzed. The composition of lipoproteins from rabbits on atherogenic diet was abnormal. The cholesterol: triglyceride ratio of every lipoprotein fraction was significantly increased as was the cholesterol: protein ratio of very low density lipoproteins. Supplementing the diet with PLURONIC FT L 61 2930 prevented these alterations. In all groups on the atherogenic diet the percentage of apolipoprotein E in VLDL and HDL increased. In the case of PLURONIC FT L 61-treated rabbits this developed even though serum cholesterol levels were normal or slightly increased. It is concluded that PLURONIC FT L 61 2930 has a systemic effect on lipoproteins which may contribute to its antiatherogenic action.Chronic Exposure or Carcinogenicity/ …Long-term administration of PLURONIC FT L 61 given in semipurified diets resulted in changes in food intake, weight gain, fecal fat output, and serum cholesterol concentrations. The composition of the diet used as the vehicle for administration had a considerable effect on these results. When semipurified diets were used, food intake and weight gain were greatest when the dietary fat content was at the highest level. When the surfactant was given in ground chow, food intake was not affected and weight gain was only slightly, but significantly, less than the controls as a result of mild fat malabsorption. It is concluded that PLURONIC FT L 61 2930 affects lipid absorption, food intake, and serum cholesterol concentration but that results of this treatment are considerably affected by dietary factors.

TR

PLURONIC FT L 61 IUPAC Ad 2-metiloksiran; oksiran

PLURONIC FT L 61 InChI InChI = 1S / C3H6O.C2H4O / c1-3-2-4-3; 1-2-3-1 / h3H, 2H2,1H3; 1-2H2

PLURONIC FT L 61 InChI Anahtar RVGRUAULSDPKGF-UHFFFAOYSA-N

PLURONIC FT L 61 Kanonik Gülüler CC1CO1.C1CO1

PLURONIC FT L 61 Moleküler Formül C5H10O2

PLURONIC FT L 61 CAS 691397-13-4

PLURONIC FT L 61 Avrupa Topluluu (EC) Numaras 618-355-0

PLURONIC FT L 61 NSC Numaras 63908

PLURONIC FT L 61 RTECS Numaras TP5950000

PLURONIC FT L 61 DSSTox Madde Kimlii DTXSID70872897

PLURONIC FT L 61 Fiziksel Tanm Sv

PLURONIC FT L 61 Renk / Form Sv

PLURONIC FT L 61 Dier Deneysel Özellikler Suda çözünmezden çok suda çözünür bileiklere kadar deiiklik gösterir.

PLURONIC FT L 61 Molekül Arl 102,13 g / mol

PLURONIC FT L 61 Hidrojen Ba Donör Says 0

PLURONIC FT L 61 Hidrojen Ba Alcs Says 2

PLURONIC FT L 61 Döndürülebilir Tahvil Says 0

PLURONIC FT L 61 Tam Kütle 102.06808 g / mol

PLURONIC FT L 61 Monoizotopik Kütle 102.06808 g / mol

PLURONIC FT L 61 Topolojik Polar Yüzey Alan 25.1 Ų

PLURONIC FT L 61 Ar Atom Says 7

PLURONIC FT L 61 Resmi Ücret 0

PLURONIC FT L 61 Karmaklk 36.7

PLURONIC FT L 61 zotop Atom Says 0

PLURONIC FT L 61 Tanml Atom Stereocenter Says 0

PLURONIC FT L 61 Tanmsz Atom Stereocenter Says 1

PLURONIC FT L 61 Tanml Bond Stereocenter Says 0

PLURONIC FT L 61 Tanmsz Ba Stereocenter Says 0

PLURONIC FT L 61 Kovalent Bal Birim Says 2

PLURONIC FT L 61 Bileik Kanonikletirilmitir Evet

Bir yüzey aktif maddeye batrlm bir süngerle yarann mekanik olarak temizlenmesi, deneysel yara enfeksiyonunun gelimesini engellemitir. Yara temizlii için kullanlan yüzey aktif madde, Pluronic polyls ad verilen bir blok kopolimer ailesinin bir üyesi olan Pluronic F-68’dir (PLURONIC FT L 61; I). Uzun süreli toksisite çalmalar ve klinik aratrmalar, bu yüzey aktif maddenin insan kullanm için güvenli olduunu göstermektedir. I, herhangi bir kendine özgü antibakteriyel aktiviteye sahip olmayan noniyonik bir deterjandr. Salinle slatlm süngerlerle mekanik temizlik bakterileri etkin bir ekilde yok etse de yaraya zarar verir ve enfeksiyona kar direncini bozar. Süngerin cilde verdii hasarn ciddiyeti, gözeneklilii ile ilikilendirilebilir. Düük gözeneklilie sahip süngerler andrcdr ve daha yüksek gözeneklilie sahip süngerlerden daha fazla cilde zarar verir. En andrc süngerlere bile I eklenmesi, doku travmas en aza indirilirken sünger frçalamann bakteriyel uzaklatrma etkinliinin korunmasn salar. Sürfaktann bu ikili etkisi, kontamine yaralarn enfeksiyon orannda dramatik bir azalma ile sonuçlanr. 36 salkl erkek denekte poloksamer 188’in (RheothRx) toksisitesi ve farmakokinetii üzerine randomize, çift kör, plasebo kontrollü, doz yükseltme çalmas yaplmtr ( 19-35 ya aras) 10-90 mg / kg / saat poloksamer veya plasebo iv enjeksiyonlar alan kiiler. … En yaygn yan etkiler ar, enjeksiyon yerinde anormallik ve mide bulantsyd. Sekiz denek, advers olaylar nedeniyle poloksamer ile tedaviyi brakt. 14C-PLURONIC FT L 61 2930 (PX), büyük moleküler arlkl noniyonik hidrofobik bir yüzey aktif madde emilimi ve atlm, safra fistül sçanlar kullanlarak çalld. ntraduodenal olarak infüze edilen dozun yaklak yars absorbe edildi ve absorbe edilen yüzey aktif maddenin bir ksm safra ile atld. Kalan ksm idrarla atld. Çalmann sonunda karacierde ve karkasta 14C-PX’in yalnzca eser miktarlar geri kazanlmtr. Diyete dahil edilmi 14C-PX ile iki çalma da gerçekletirildi. 7 günlük ilk besleme çalmasnda, ajann çou, tedavinin kesilmesinden sonraki 72 saat içinde gastrointestinal sistem yoluyla atld. kinci çalmada, test süresi uzadkça yüzey aktif maddenin vücutta birikmeye devam edip etmediini belirlemek için farelere 7, 14 veya 23 gün boyunca 14C-PX diyetiyle beslendi. 7. ve 14. günler arasnda daha fazla birikme meydana geldi, ancak toplam 23 gün boyunca beslemeye devam edildiinde deil. 23 günlük beslemeden sonra alnan 14C-PX miktarnn esasen tamam tedavinin kesilmesinden sonraki 7 günün sonunda atld. Bu çalmalar, yaklak 3.000’lik büyük moleküler arlna ramen baz 14C-PX’in emildiini göstermektedir. Ayrca emilen materyal, vücut dokularnda çok az tutularak safra ve idrarda hzla atlr. Poloksamer 407’nin (Pluronic F-127) dalmn aratrmak için sçanlara 300 mg intraperitoneal poloksamer 407 solüsyonu verildi; sk sk kan ve idrar örnekleri alnd ​​ve karacier ve böbrek homojenatlar bir kolorimetre testi kullanlarak hazrland ve analiz edildi. Klirens 0.014 mL / dk idi. drarla atlan ortalama miktar 24 saatte 76.3 mg idi. Karacier ve böbrek homojenatlarnn süpernatanlarndaki poloksamer 407 miktarlar srasyla 15.9 ve 3.1 mg idi. Poloksamer 108’in dalm ve farmakokinetii, insandaki davrann anlamaya yönelik ilk adm olarak farelerde çalld. Sçanlarda iv uygulamadan sonra, 7 veya 100 mg / kg etilen-14-C-etiketli polimer dozlarnn yaklak% 94’ü atlmtr.3 gün içinde idrarda. Etiketin yaklak% 6’s dkda göründü. Eritrosit zarlar polimere geçirgen deildi ve idrarda sadece ana bileik gösterilebilirdi. Dozlamadan yirmi saat sonra, küçük kalntlar sadece böbrek, karacier, ince barsak ve karkasta tespit edildi. Plazma kaybolma modelinin 3. faz sadece daha büyük dozda belirgindi, ancak plazma kaybolma kinetii kullanlan aralktaki dozdan bamszd. Poloxamer 108’in çou, sçanlarda renal atlm yoluyla hzla elimine edildi; muhtemelen daha küçük bir ksm safra atlm ile uzaklatrlmtr. iv alan 36 salkl erkek denekte (19-35 ya aras) poloksamer 188’in (RheothRx) toksisitesi ve farmakokinetiinin randomize, çift kör, plasebo kontrollü, doz yükseltme çalmas yaplmtr. 10-90 mg / kg / saat poloksamer veya plasebo enjeksiyonlar. Poloksamer esas olarak renal atlmla elimine edildi. Kararl durumda klirens, eliminasyon hz sabiti ve görünen dalm hacmi tahminleri, infüzyon hzndan bamszdr. Kararl durum plazma seviyeleri, 90 mg / kg / saate kadar yükselen infüzyon hz deerleri ile dorusal olarak artmtr. Ortalama plazma klirensi 1.06 mL / dak / kg idi. Analit: PLURONIC FT L 61; matris: kimyasal tanmlama; prosedür: amonyum tiyosiyanat, kobalt nitrat ve etilen klorür ile görsel reaksiyon (mavi renk) .Analit: PLURONIC FT L 61; matris: kimyasal saflk; prosedür: 630 nm’de tespit ve standartlarla karlatrma ile ultraviyole absorpsiyon spektrofotometrisi. Yeni hayvan ilaçlarndan oral dozaj: PLURONIC FT L 61. (a) Spesifikasyonlar. Polioksipropilen-polioksietilen glikol noniyonik blok polimer. … Kullanm Koullar. (1) Srlarda baklagil (yonca, yonca) kabuunun tedavisi için. (2) Srlarda baklagil (yonca, yonca) kabuunun kontrolü için. (3) Srlarda baklagil (yonca, yonca) ve buday mera ikinliinin önlenmesi için. (4) Srlarda baklagil (yonca, yonca) ve buday meras ikinliinin kontrolü için. Hayvan yemlerinde kullanlmak üzere yeni hayvan ilaçlar: PLURONIC FT L 61. (a) Onaylar. (1) Kuru Tip A ilaçl ürünler: Bu bölümün 510.600 (c) ‘sinde yüzde 53 ila 000069. (2) Sv Tip A ilaçl ürünler: Bu bölümün 510.600 (c) ‘sinde yüzde 99.5 ila 000069. (b) Kullanm koullar. (1) Srlarda baklagil (yonca, yonca) ve buday mera ikinliinin önlenmesi için Hayvan yemlerinde kullanlmak üzere yeni hayvan ilaçlar: PLURONIC FT L 61 serbest seçimli sv Tip C yem. (a) Onaylar. A Tipi ilaçl makaleler: Bu bölümün 510.600 (c) ‘sinde yüzde 99.5 ila 066104. (b) Kullanm koullar. (1) Srlarda baklagil (yonca, yonca) ve buday mera ikinliinin kontrolü için … (2) Büyükba baklagillerin otlatlmasnda baklagil (yonca, yonca) ikinliinin kontrolü için PLURONIC FT L 61, izin verilen bir gda katk maddesidir Akut Maruz Kalma / Hidrofobik yüzey aktif madde PLURONIC FT L 61 2930’un lipid emilimi üzerindeki etkisi sçanlarda incelenmitir. Sürfaktann intraduodenal olarak alanm olduu akut koullar altnda, enterositlerde anormal bir ekilde biriken lipid emilen bir lipid ile alanmtr. Bu etki, tedavinin sonlandrlmasndan sonra hzla tersine döndü. Hidrofobik bir yüzey aktif madde olan PLURONIC FT L 61 2930, doz seviyelerinde, diyetin% 0.5 ve% 1’inde aterojenik bir diyete dahil edildi ve 10 hafta boyunca tavanlara verildi. Baka bir gruba tek bana düz aterojenik diyet verildi ve bir kontrol grubuna yemi verildi. Bu sürenin sonunda serum lipoproteinleri santrifüj ile ayrld ve analiz edildi. Aterojenik diyette tavanlardan elde edilen lipoproteinlerin bileimi anormaldi. Her lipoprotein fraksiyonunun kolesterol: trigliserit oran, çok düük younluklu lipoproteinlerin kolesterol: protein oran gibi önemli ölçüde artmtr. Diyetin PLURONIC FT L 61 2930 ile takviye edilmesi bu deiiklikleri önledi. Aterojenik diyet uygulanan tüm gruplarda, VLDL ve HDL’deki apolipoprotein E yüzdesi artmtr. PLURONIC FT L 61 ile muamele edilmi tavanlar durumunda bu, serum kolesterol seviyeleri normal olsa veya hafifçe artm olsa bile gelimitir. PLURONIC FT L 61 2930’un, antiaterojenik etkisine katkda bulunabilecek lipoproteinler üzerinde sistemik bir etkiye sahip olduu sonucuna varlmtr. , kilo alm, dkda ya çk ve serum kolesterol konsantrasyonlar. Uygulama için araç olarak kullanlan diyetin bileimi, bu sonuçlar üzerinde önemli bir etkiye sahipti. Yar saflatrlm diyetler kullanldnda, besin alm ve kilo alm, diyetteki ya içerii en yüksek seviyede olduunda en yüksek seviyedeydi. Sürfaktan öütülmü yemde verildiinde, gda alm etkilenmedi ve kilo art, hafif ya emiliminin bir sonucu olarak kontrollere göre sadece hafif, ancak önemli ölçüde daha azd. PLURONIC FT L 61 2930’un lipid emilimini, gda almn ve serum kolesterol konsantrasyonunu etkiledii, ancak bu tedavinin sonuçlarnn diyet faktörlerinden önemli ölçüde etkilendii sonucuna varlmtr.